K+ will be amongst the performers this year and their results will have little to do with vaccine news. for those who actually take time to understand how a vaccine is created and executed will understand.

thank you @gemstar

did they announce any dividend ?

Also from The Edge: "as at Dec 31, 2019, Scomnet had net cash of RM 46.14 million and zero borrowings.".

Very promising quarters and years ahead for Scomnet.

It's only comparable to fundamentals if it sticks to exactly the same product offering and strategy. in a JV like this cross-selling and cross-sharing of customer segments will happen for sure. I believe k+ would be open minded for new ideas, otherwise the jv wouldn't have happened. i have good faith that k+ will see good results this year.

my two cents why k+ will continue its uptrend aggresively.

the Covid19 outbreak has prompted a significantly higher interest to continue heavy investments into glove making sectors. Covid19 is an obvious indicator that demand will continue to exceed supply.

specifically for k+, consider the JV that has recently pulled through. this JV will bring k+ to new heights; a JV has to benefit both parties. K+'s core strength may be in production and combined with Ansell's distribution expertise, there is only one way ahead - forward.

K+ may not have been ideally profitable for past qtrs or years but i believe Ansell will do what they can to quickly turn this around, if they haven't already started. with Ansell as its' partner, it would be rather easy for K+ products to penetrate better and more profitable markets. K+ doesn't need to fight other glove leaders head on, the pie is large enough to share.